New Clinical Trial Data on Crohn’s Disease Treatment Filgotinib Reported by Galapagos

New Clinical Trial Data on Crohn’s Disease Treatment Filgotinib Reported by Galapagos
Beglium-based Galapagos NV recently reported additional data from its Phase 2 FITZROY clinical trial assessing filgotinib, a selective JAK1 inhibitor being investigated for the treatment of Crohn's disease. The FITZROY trial assessed the efficacy and safety of filgotinib (200 mg once daily) versus placebo in 174 patients with moderate to severe active Crohn's disease, either anti-TNF naive or anti-TNF failures. In December 2015, the company reported the results from the first 10 weeks of the study, revealing that the primary endpoint of clinical remission was met. Specifically, the data showed that the percentage of patients achieving a Crohn's Disease Activity Index (CDAI) score lower than 150 was superior in patients receiving treatment wit
Subscribe or to access all post and page content.

2 comments

Leave a Comment

Your email address will not be published. Required fields are marked *